All posts by medical

Greys Anatomy Season 16 Is Now On Netflix. Is Meredith Grey Still its Star? – Refinery29

While Meredith is helping Andrew blaze his own road to history, Amelia is giving birth to a baby fans have waited all season to meet with a nod to Greys history, no less and Teddy is accidentally sending a voicemail of herself en flagrante to Owen, whom is was supposed to marry that evening. This is jaw-dropping, heartstring-pulling stuff. Meredith, in her final scene of Happy Face, is simply left to pick Andrew up off the floor and carry him home.

Original post:
Greys Anatomy Season 16 Is Now On Netflix. Is Meredith Grey Still its Star? - Refinery29

Biosimilars in Immunology Market 2020: Qualitative Analysis of the Leading Players and Industry Scenario – 3rd Watch News

Biosimilars in Immunology Thematic Analysis report combines key opinion leader insight and interviews with payers in the US, France, Germany, Italy, Spain, the UK, Japan, India and South Korea to provide an in-depth review of the biosimilars market for major autoimmune diseases.

The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena.

Request Free Sample Pages Of This Premium Research Report:https://www.researchmoz.us/enquiry.php?type=S&repid=2619152

Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.

Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burden; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.

Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by GlobalData indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.

Other reasons against switching included lack of incentives for physicians, lack of switching data, and nocebo effects.Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen.

In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.

Scope

Components of the report include Introduction toBiosimilars in Immunology-Defining biosimilars in immunology and discussing the history of drugs approved across the 9MM. Assessment of Marketed and Pipeline Products- An overview of biosimilar products on the market and drugs currently in clinical development. Regulatory Strategies-Overview of biosimilar regulatory strategies by country. Market Dynamics Overview of biosimilar market dynamics by country. Focus Indicationsand Market Potential In-depth assessment of biosimilars in major autoimmune indications, market potential as well as drivers and barriers to uptake.

Inquire More About This Report @https://www.researchmoz.us/enquiry.php?type=E&repid=2619152

Reasons to Buy

Key Players In-depth assessment of key players in the space across the 9MM Key Clinical and Commercial Concepts- An examination of key clinical and commercial concepts in the biosimilars in immunology space, based on KOL and payer insights. Pricing and reimbursement infrastructure and challenges are examined. Future Opportunities- Overview of future strategies recommended by KOLs and payers for boosting biosimilar uptake is discussed.

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on :http://marketresearchlatestreports.blogspot.com/

Read the rest here:
Biosimilars in Immunology Market 2020: Qualitative Analysis of the Leading Players and Industry Scenario - 3rd Watch News

Newly Discovered Dendritic Cell Important in Respiratory Infections – Technology Networks

With a discovery that could rewrite the immunology textbooks, an international group of scientists, including the teams of Bart Lambrecht, Martin Guilliams, Hamida Hammad, and Charlotte Scott (all from the VIB-UGent Center for Inflammation Research) identified a new type of antigen-presenting immune cell. These cells, that are part of an expanding family of dendritic cells, play a crucial role presenting antigens to other immune cells during respiratory virus infections, and could explain how convalescent plasma helps to boost immune responses in virus-infected patients.

When our body faces an infection, it responds with inflammation and fever. This is a sign that the immune system does its work, and leads to the activation of many cells, like soldiers in an army. Dendritic cells (DCs) are the generals of that army. They can precisely activate and instruct the soldiers to kill infected cells by presenting antigens derived from the invaders to cells of the immune system.

There are several types of DCs that perform antigen-presenting functions in the body. A first type of conventional DCs continuously scan the body for dangerous invaders, even when there is no infection. When there is inflammation triggered by infection, another subset of DCs emerges from inflammatory monocytes. Because monocyte-derived DCs are easily prepared in vitro from monocytes isolated form human blood, it was always assumed these cells were very important antigen-presenting cells. Clinical trials using monocyte-derived DCs in cancer therapy have however been disappointing.

A study by the teams of Bart Lambrecht, Martin Guilliams, Hamida Hammad, and Charlotte Scott (all from the VIB-UGent Center for Inflammation Research) and international colleagues, shows that monocyte-derived DCs are poor antigen-presenting cells, but have wrongly been assumed to have these functions because of a case of mistaken identity.

The scientists studied mice with a viral respiratory infection (pneumonia virus of mice and influenza virus) with single-cell technologies. This single-cell resolution allowed them to finely separate the monocyte-derived cells from other DCs during their response to the infection. They found that monocyte-derived DCs do exist, but actually do not present antigens. The reason for all the confusion in the past is that a look-alike new DC emerges called inflammatory type 2 conventional DC, or inf-cDC2 that combines some of the best characteristics of monocytes, macrophages, and conventional DCs, to induce the best form of immunity.

Bart Lambrecht: This was a big surprise for us. Weve all been taught that monocyte-derived cells are excellent antigen presenting cells, certainly when theres inflammation. Now, we show that its actually a new hybrid DC type thats doing all the work. This really changes what we know about the immune system and is very important knowledge for understanding respiratory viral infections and other inflammatory diseases.

Martin Guilliams: It took a massive team effort but the strength of single-cell sequencing has finally cracked the complex DC code. Many contradicting findings from the last two decades now make much more sense. This also opens tremendous therapeutic opportunities, since vaccination strategies can now be designed to trigger formation of inf-cDC2s and thus generate a stronger antiviral immune response.

Charlotte Scott: Through the use of single cell technologies we have been able to align all the findings from the past few years and identify the distinct cell types involved. Moving forward it will be very interesting to see under what other inflammatory conditions these inf-cDC2s are generated and how they can potentially be targeted therapeutically.

The findings of the researchers also have a direct relevance for the current COVID-19 pandemic, caused by another respiratory virus. An emergency treatment that is currently being explored is the use of convalescent plasma, or the blood plasma of recovered patients.

Cedric Bosteels, lead author of the new paper: One of the unique features of the new DCs is that they express functional Fc receptors for antibodies that are found in the plasma of patients who have recovered from COVID-19

This study is the first to show that one of the mechanisms through which convalescent plasma and the virus-specific antibodies in it work, is via boosting of inf-cDC2. Since boosted DCs induce a much stronger immune response, this study reveals a new target for therapeutic intervention for viral infections and other inflammatory diseases.

ReferenceBosteels, Neyt, et al. (2020). Inflammatory Type 2 cDCsAcquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection. Immunity. 52: 1 18. Doi: j.immuni.2020.04.005.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
Newly Discovered Dendritic Cell Important in Respiratory Infections - Technology Networks

Do Antibodies Against The Novel Coronavirus Prevent Reinfection? : Shots – Health News – NPR

A medical worker walks in front of Transform MD Medical Center in White Plains, N.Y., where antibody testing was being offered. Pablo Monsalve/VIEW press/Corbis via Getty Images hide caption

A medical worker walks in front of Transform MD Medical Center in White Plains, N.Y., where antibody testing was being offered.

Most people infected with the novel coronavirus develop antibodies in response.

But scientists don't know whether people who have been exposed to the coronavirus will be immune for life, as is usually the case for the measles, or if the disease will return again and again, like the common cold.

"This to me is one of the big unanswered questions that we have," says Jeffrey Shaman, a professor of environmental health sciences at Columbia University, "because it really says, 'What is the full exit strategy to this and how long are we going to be contending with it?' "

He's one of many scientists on a quest for answers. And the pieces are starting to fall into place.

Antibodies, which are proteins found in the blood as part of the body's immune response to infection, are a sign that people could be developing immunity. But antibodies are by no means a guarantee a person will be protected for life or even for a year.

Shaman has been studying four coronaviruses that cause the common cold. "They're very common and so people seem to get them quite often," Shaman says. Ninety percent of people develop antibodies to those viruses, at least in passing, but "our evidence is those antibodies are not conferring protection."

That may be simply because colds are relatively mild, so the immune system doesn't mount a full-blown response, suggests Stanley Perlman, a pediatrician who studies immunology and microbiology at the University of Iowa. "That's why people get colds over and over again," he says. "It doesn't really tickle the immune response that much."

He's studied one of the most severe coronaviruses, the one that causes SARS, and he's found that the degree of immunity depended on the severity of the disease. Sicker people remained immune for much longer, in some cases many years.

For most people exposed to the novel coronavirus, "I think in the short term you're going to get some protection," Perlman says. "It's really the time of the protection that matters."

Perlman notes that for some people the symptoms of COVID-19 are no worse than a cold, while for others they are severe. "That's why it's tricky," he says, to predict the breadth of an immune response.

And it's risky to assume that experiences with other coronaviruses are directly applicable to the new one.

"Unfortunately, we cannot really generalize what kind of immunity is needed to get protection against a virus unless we really learn more about the virus," says Akiko Iwasaki, a Howard Hughes Medical Institute investigator at the Yale University School of Medicine.

An immunobiologist, she is part of a rapidly expanding effort to figure this out. She and her colleagues are already studying the immune response in more than 100 patients in the medical school hospital. She's encouraged that most people who recover from the coronavirus have developed antibodies that neutralize the coronavirus in a petri dish.

"Whether that's happening inside the body we don't really know," she cautions.

Research like hers will answer that question, eventually.

But not all antibodies are protective. Iwasaki says some can actually contribute to the disease process and make the illness worse. These antibodies can contribute to inflammation and lead the body to overreact. That overreaction can even be deadly.

"Which types of antibodies protect the host versus those that enhance the disease? We really need to figure that out," she says.

The studies at Yale will follow patients for at least a year, to find out how slowly or quickly immunity might fade. "I wish there was a shortcut," Iwasaki says, "but we may not need to wait a year to understand what type of antibodies are protective."

That's because she and other immunologists are looking for patterns in the immune response that will identify people who have long-term immunity.

Researchers long ago figured out what biological features in the blood (called biomarkers) correlate with immunity to other diseases, says Kari Nadeau, a pediatrician and immunologist at the Stanford University School of Medicine. She expects researchers will be able to do the same for the new coronavirus.

Nadeau is working on several studies, including one that seeks to recruit 1,000 people who were previously exposed to the coronavirus. One goal is to identify people who produce especially strong, protective antibody responses. She says the antibody-producing cells from those people can potentially be turned into vaccines.

Another critical question she's zeroing in on is whether people who become immune are still capable of spreading the virus.

"Because you might be immune, you might have protected yourself against the virus," she says, "but it still might be in your body and you're giving it to others."

It would have huge public health implications if it turns out people can still spread the disease after they've recovered. Studies from China and South Korea seemed to suggest this was possible, though further studies have cast doubt on that as a significant feature of the disease.

Nadeau is also trying to figure out what can be said about the antibody blood-tests that are now starting to flood the market. There are two issues with these tests. First, a positive test may be a false-positive result, so it may be necessary to run a confirmatory test to get a credible answer. Second, it's not clear that a true positive test result really indicates a person is immune and, if so, for how long.

Companies would like to be able to use these tests to identify people who can return to work without fear of spreading the coronavirus.

"I see a lot of business people wanting to do the best for their employees, and for good reason," Nadeau says. "And we can never say you're fully protected until we get enough [information]. But right now we're working hard to get the numbers we need to be able to see what constitutes protection and what does not."

It could be a matter of life or death to get this right. Answers to these questions are likely to come with the accumulation of information from many different labs. Fortunately, scientists around the world are working simultaneously to find answers.

You can contact NPR Science Correspondent Richard Harris at rharris@npr.org.

View original post here:
Do Antibodies Against The Novel Coronavirus Prevent Reinfection? : Shots - Health News - NPR

Changes to the Roche Enlarged Corporate Executive Committee – Benzinga

Basel, 11 May 2020 - Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July. Aviv Regev (1971), Ph.D., and currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator of the Howard Hughes Medical Institute, will join Genentech as the new Head of gRED and will become a member of the enlarged Corporate Executive Committee as of 1 August 2020. She will be based in South San Francisco.

Commenting on the appointment, Roche's CEO Severin Schwan said: "I am very excited to have Aviv Regev joining us. She brings a rare combination of expertise that will help us unlock even more possibilities in data-based drug discovery and development." Schwan further commented: "I have tremendous gratitude for Mike's many contributions over the past fifteen years including expanding our drug platform capabilities and the positive impact he has made to the strength of our pipeline. I wish him continued happiness and health in his retirement."

Aviv Regev has a Ph.D. in computational biology and Master of Science from Tel Aviv University. Through her pioneering efforts she is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. In particular, she has pioneered assays for RNA sequencing in single-cells, machine learning algorithms for distilling biological knowledge from the resulting information, and many of the first demonstrations of how to yield foundational new insights into an extraordinarily wide range of molecular circuits, systems, and fields, including immunology, neurobiology, development, inflammatory disease, cancer, and evolution. In doing so, her groundbreaking work is helping to answer the deepest and most general of biological questions -- how cells and their circuits function and rewire, and how these dynamics underlie health and malfunction in disease.

In addition to her current roles, she holds further responsibilities as founding co-chair of the international Human Cell Atlas project and founding Director of the Klarman Cell Observatory at Broad Institute. Prior to joining MIT and the Broad, she was a Bauer Fellow for the Center for Genomics Research at Harvard University. Beyond her many scientific publications, she has been recognized with numerous designations and awards such as member of the National Academy of Sciences, recipient of the Paul Marks Prize from Memorial Sloan Kettering Cancer Center, and the Innovator Award from the International Society for Computational Biology. She serves on multiple corporate advisory, scientific advisory, and journal editorial boards, and served on the advisory committee to the National Human Genome Research Institute at the National Institutes of Health. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com - Nicolas Dunant (Head) - Patrick Barth - Daniel Grotzky - Karsten Kleine- Nathalie Meetz - Barbara von Schnurbein

Visit link:
Changes to the Roche Enlarged Corporate Executive Committee - Benzinga

Expert says he’s now ‘begging the Government’ to change guidelines on face masks – Newstalk

An immunology expert says he is now 'begging the Government' to change the guidelines and recommend the wearing of face masks in public.

It comes amid increasing calls for clarity and guidance for the public on face coverings as part of the phased reopening of the country in the coming weeks and months.

The National Bus and Rail Union (NBRU) has called for the compulsory wearing of masks for all commuters to protect staff and 'enhance customer confidence'.

Officials have indicated that the use of face coverings in the community will be part of the efforts to ease social distancing measures over the summer.

However, the public has not yet been advised by health officials to wear masks when out and about.

Luke ONeill - Professor of Biochemistry at the School of Immunology at Trinity College Dublin - spoke to The Pat Kenny Show about why he believes people should be covering their faces while out shopping or on public transport.

Expert says he's now 'begging the Government' to change guidelines on face masks

00:00:00 / 00:00:00

He said the situation regarding masks in Ireland remains gob-smacking

He observed: I go into work at the moment, and Im on the DART: nobody was wearing a mask.

I went out to Tesco and got myself a sandwich for lunch: again, nobody was wearing a mask.

Prof ONeill noted that the evidence regarding mask-wearing has grown stronger and stronger and stronger.

He said: "The Royal Society, a very famous institution, issued a big report two days ago summarising the evidence the best brains in the world say you have to wear a mask in a supermarket or on public transport.

Im begging the Government now to change the guidelines.

He said its vital there are adequate supplies of protective equipment for healthcare workers and that the public is well-informed on how to use masks properly.

However, he stressed: The evidence is clear: it helps decrease spread. Its obvious in a way, isnt it?

Im pretty sure the Government will change the guidelines on this - we hope so soon."

Prof O'Neill also stressed that people shouldn't feel awkward about wearing masks in public.

He suggested: "Don't worry about yourself - it's the other person you're protecting. That's the key thing."

Main image: File photo. Photograph: Sasko Lazarov / RollingNews.ie

View original post here:
Expert says he's now 'begging the Government' to change guidelines on face masks - Newstalk

The way to beat coronavirus (COVID-19) from testing to vaccination – ILoveQatar.net

Immunology expert Dr. Richard OKennedy, Qatar Foundation Vice President for Research, Development, and Innovation, explains how COVID-19 testing works - and why developing a vaccine takes time.

The rapid pace at which coronavirus continues to spread across the world has inevitably raised questions about testing, vaccines, and potential treatments including why testing for the virus appears difficult and time-consuming, how long a vaccine will take to develop, and how it will work once it has been developed.

Dr. Richard OKennedy, Qatar Foundation Vice President for Research, Development, and Innovation, and an immunology expert, says:

Adding to the complexity of developing accurate testing kits is the urgency with which the world is seeking these tests. However, as Dr. OKennedy points out, the companies developing them need to ensure they are validated and approved before they can move to the mass manufacturing stage, with the process rendered even more difficult due to the speed with which coronavirus (COVID-19) cases worldwide have risen:

A vaccine for coronavirus (COVID-19) has been the subject of discussion since the start of the outbreak, with such conversations often failing to recognize that the vaccine development process can take as long as 10-15 years. However, given the severity and ever-changing consequences of the current global pandemic, specialists in several countries are working around the clock on research that is aimed at developing a vaccine within a much shorter timescale.

As Dr. OKennedy explains, the immune system is essentially a series of defense mechanisms within the human body. People can play their own part in ensuring something that may look to attack their body does not have the opportunity to do so, which explains why healthcare professionals unanimously agree that the best course of action is to keep washing hands and observe social distancing guidelines.

When an infection does get through these precautions, the immune system creates antibodies to fight and counteract it. However, every so often, a virus such as the coronavirus (COVID-19) mutates and evades the human immune system.

Dr OKennedy said

A vaccine can be described as something that activates or primes the immune system. The way the polio vaccine the success rate of which has contributed to the near-elimination of polio worldwide works, for instance, is that the human immune system is exposed to a small, inactive dose of the virus to activate an immune response. This immune response allows the body to defend itself against the virus.

Dr. OKennedy said.

The consequences of prematurely introducing a vaccine that turns out to be unsafe are potentially severe. In order to prevent this, vaccines go through rigorous testing and clinical trials, contributing to the timescales involved in introducing them.

In the meantime, the global medical community is exploring potential treatments using combinations of existing drugs. One that has gained a high profile is Chloroquine, an antimalarial drug, but its effectiveness is subject to trial results.

Dr. OKennedy said:

Source: QF

Liked this article? Share it!

Excerpt from:
The way to beat coronavirus (COVID-19) from testing to vaccination - ILoveQatar.net

Coronavirus isolation affects your brain a neuroscientist explains how, and what to do about it – ABC News

After weeks of living in the coronavirus shutdown, for people in many parts of Australia restrictions are finally beginning to lift.

But have you noticed that as the weeks passed in isolation, you found you couldn't think as clearly, that you were lethargic, less productive, your mental health deteriorated, or that your attention span dwindled?

Or, paradoxically, maybe you had a strange surge in productivity?

But iso life isn't completely over yet. So let's take a look at how living in isolation affects the brain, and what we can do about it.

We can get a better understanding of how our brains are responding to COVID-19 isolation when we look at past research on people and animals who have been isolated. For example, people travelling in space or imprisoned in solitary confinement, or animals in captivity all give us clues.

When we are faced with danger, our brains release hormones that trigger the "flight or flight" response.

This serves two main functions it helps prepare our body to fight the threat or escape to safety, and it also encourages us to band together.

The evolutionary basis for this is survival a cohesive group is more likely to survive a threat.

Get the latest health news and information from across the ABC.

The thing is, the body reacts the exact same way to modern-day stresses, such as dealing with the COVID-19 pandemic.

And because this situation is constant for many of us, we find ourselves in a state of chronic stress.

Chronic stress affects the cells in our body right down to the level of our genes.

This explains why some people are having a hard time holding things together, while others are finding that they are the most productive they've been in years.

Stress is fundamentally a process that allows our body to function most effectively, to meet the challenges faced at the time which is why some people report performing much better during isolation.

However, a body and brain that are chronically stressed are focused on survival.

Being in survival mode comes at the expense of our most sophisticated behaviours our decision-making skills, our problem solving, our creativity and we revert back to our more primitive behaviours, such as anger, fear and aggression.

During chronic stress, the part of our brain involved in initiating the fight or flight response, and the generation of our emotions, a region called the amygdala, grows in size as it adapts to the high levels of stress hormones, such as cortisol.

However, larger amygdalas are correlated with more aggression across all species which is why you might find yourself angrier or more emotional.

When we're stressed, our brain releases a little burst of the hormone oxytocin, as a coping mechanism.

Oxytocin is responsible for that feeling of being close and connected to someone and it drives us to seek connection with others.

Why does our brain release a "bonding" hormone when we're stressed?

It serves a really important evolutionary purpose it is trying to help us survive.

It makes us crave that connection with someone, so that when we're stressed, we seek safety in numbers. We reach out for help, we talk our problems through with a friend, and we ultimately feel better.

Researchers have also observed the part of our brain involved in decision making, known as the prefrontal cortex, shrinking and becoming more disconnected from other brain areas in response to long-term stress. So if you've been struggling to focus and be productive, this could be why.

The prefrontal cortex is important for problem solving, attention, regulating our emotions, and our complex behaviours like personality and creativity.

Breaking down the latest news and research to understand how the world is living through an epidemic, this is the ABC's Coronacast podcast.

Just because there's a biological reason behind why your brain's functioning a little differently right now doesn't mean you can't take control.

Here are five aspects of your life that you might feel are a little wonky at the moment, and what you can do about it.

For over 50 years, we have known that people who are more socially isolated are more likely to die.

The 29 per cent increased risk in mortality for people who have spent years in social isolation is largely due to the effects of chronic stress on the body.

When we are socialising with someone we like, our brain releases a cocktail of hormones and neurotransmitters, which helps us feel closer to that person, happier, and even reduces pain.

Socialising activates our brain's reward system, which makes us feel good.

This is the same part of the brain that makes food taste great when we're hungry, or is responsible for you feeling elated when your favourite sports team wins a game. It also drives addiction.

And socialising doesn't just make us bond with people, it also makes us feel better, by reducing the levels of stress hormones, like cortisol, in our body.

You might have noticed that talking on the phone to a loved one leaves you feeling better than texting alone does.

This is because text messaging activates the brain's reward pathway, but it doesn't seem to result in the release of oxytocin.

In addition to social connection, it seems that connection to self is important too. Mindfulness, meditation and yoga have been shown to help reverse stress-related changes in the brain.

Social media makes it possible for us socialise far and wide. Reach out to friends online, call your parents, and learn how to practice mindfulness or meditation.

Social deprivation is one thing. What about sensory deprivation?

Many of us are already living in small apartments in a concrete jungle, and being in isolation has restricted our ability to get outdoors.

When mice are housed in isolation, the levels of certain growth factors in their brain changes after just two weeks.

We have the same growth factors in our brain, though to date it has not been possible to measure this in living humans.

These growth factors are a bit like a brain "fertiliser," and keep the cells in the brain working optimally, and helping them survive.

So it isn't surprising to hear that after mice had been placed in one month of social isolation, neurons in the sensory and motor regions of the brain had shrunk by 20 per cent.

Having low levels of these growth factors are associated with an increased risk of anxiety and depression, which is why you may have noticed your mental health deteriorate.

The good news is, we know that spending time in nature can help reverse the effects stress on the body. Just 20 minutes in a green space reduces our stress hormone cortisol levels by 18.5 per cent.

Head to the backyard for a dose of nature, or if you're in an apartment with no nature to gaze at, be sure to get to a green space for your exercise.

Depression disrupts sleep. When we look at the brains of people who are depressed, scientists have found that genes involved in our sleep-regulating circadian rhythm change.

Even if you aren't feeling depressed, you may still have noticed your sleep cycles change in isolation.

Much of this is likely due to a disruption in your routine, and a lack of exposure to light. Exposure to light delays the release of sleep-inducing melatonin.

Some of us are having strange dreams, or even nightmares. In isolation, many of us are sleeping longer and waking up more naturally, which is associated with having heightened dream recall.

Our dreams are composed of elements of our daily life experiences. When we sleep, our important memories throughout the day are shuttled into long-term memory storage.

Some of this occurs in the "shallow" stage of sleep, known as the REM stage, where we experience dreams and are easily woken. You won't remember your dreams if you are woken up in deep sleep.

We cycle from REM sleep to deep sleep and back to REM sleep approximately every 90 minutes.

Withdrawal from our daily routine has starved our dreams of "inspiration," forcing our subconscious to draw more heavily from past experiences.

The more anxiety we feel about our life, the more negative our dreams tend to be.

To help improve your sleep, try sticking to a routine and avoid screen time for at least an hour before bed. And lay off the alcohol it reduces the quality of your sleep.

Many of us are finding that we spending more time vegetating on the couch and aren't getting enough or any physical activity.

Among many other things, exercise increases blood flow to the brain, and raises the levels of these "brain fertiliser" growth factor compounds. It also stimulates the formation of new brain cells.

New brain cells are integrated into our brain circuits and are crucial for learning and memory.

Feeling forgetful and struggling to learn during isolation? Thirty minutes of moderate intensity exercise every second day may help change this.

In fact, just 10 minutes of exercise may improve our attention for the following two to four hours, so if you're struggling to focus, get that blood pumping.

Want even more science, health and tech? Join the conversation on Facebook.

Have you found yourself overeating or binge-eating? Emotional or comfort eating occurs when we try to suppress negative emotions with food.

Our body's stress response takes a lot of energy, which is why stress increases our preference for calorie rich foods.

Those tasty sweets result in the release of release of dopamine in our brain's reward centre. This is why they make us feel good in the short term.

Unfortunately, long term high-fat or high-sugar diets impair brain function by increasing inflammation and reducing neuroplasticity, that is, how adaptable our brain is.

This is why you may be struggling to learn after binging on junk food over the past month.

Give your isolation brain a boost by laying off the high-sugar or high-fat treats. Have healthy snacks on hand instead, like fruit, vegetables and nuts.

Dr Lila Landowski is a research fellow in neuroscience and brain plasticity at the School of Medicine, University of Tasmania.

Loading...

Read the original:
Coronavirus isolation affects your brain a neuroscientist explains how, and what to do about it - ABC News

COVID-19 pandemic NEUROSCIENCE ANTIBODIES AND ASSAYS Market 2019 Future growth, new developments, and industry analysis Research Report – Cole of…

Research report on NEUROSCIENCE ANTIBODIES AND ASSAYS Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, NEUROSCIENCE ANTIBODIES AND ASSAYS Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

Report Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

Download Premium Sample Copy Of This Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=268&RequestType=Sample

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market to reach USD 5.1 billion by 2025.

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market valued approximately USD 2.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2017-2025. The increasing automation of high-throughput screening and the availability of robust data management software tools, which enable researchers to develop systemic and process-oriented approaches toward neuroscience antibodies and assays techniques are some of the factors contributing to the growth of this segment.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product oReagents oInstrumentsBy TechnologyoImmunoassayoMolecular DiagnosticsBy End UseroResearch InstitutesoHospitalsBy Regions:oNorth AmericaoU.S.oCanadaoEuropeoUKoGermanyoAsia PacificoChinaoIndiaoJapanoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015Base year 2016Forecast period 2017 to 2025

Some of the key manufacturers involved in the market are. Thermo Fisher Scientific, Abcam, Bio-Rad, Merck KGAA, Cell Signaling Technology, Genscript, Rockland Immunochemicals. Bio Legend, Santa Cruz Biotechnology, Tecan, F. Hoffmann-La Roche, Siemens. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global NEUROSCIENCE ANTIBODIES AND ASSAYS in Market Study:

oKey Consulting Companies & AdvisorsoLarge, medium-sized, and small enterprisesoVenture capitalistsoValue-Added Resellers (VARs)oThird-party knowledge providersoInvestment bankersoInvestors

Have Any Query Or Specific Requirement? : https://brandessenceresearch.biz/Request/Sample?ResearchPostId=268&RequestType=Customization

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market.

Market Forecast:Here, the report offers a complete forecast of the Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://apnews.com/bb6aa419e9306aa39c0967cbaf8359f7

https://www.marketwatch.com/press-release/at-1729-cagr-intelligent-vending-machine-market-2019-share-upcoming-trends-segmentation-and-forecast-to-2025-2020-04-01

https://apnews.com/236d33cfeea1ad301626edb3bb553db1

See the original post:
COVID-19 pandemic NEUROSCIENCE ANTIBODIES AND ASSAYS Market 2019 Future growth, new developments, and industry analysis Research Report - Cole of...

Our pupils follow rhythms that arise in the environment – Tech Explorist

Our pupils also dilate when we see someone were attracted to. It controls the amount of light entering the eye and hits the retina. To control the amount of light that hits the retina, our iris, the colored part, acts as a shutter, expanding or contracting to determine how much light gets through the pupil.

Neuroscientists from the German Primate Center (DPZ) Leibniz Institute for Primate Research and the European Neuroscience Institute Gttingen have now discovered in an investigation of humans and rhesus monkeys that the measure of incident light doesnt just reflexively constrain the movement of the pupil, but unconsciously also by our brain. In this way, the pupil can follow rhythms that rise in the environment.

In this manner, the opening of the pupil is optimally adapted to our environment, which enhances perception.

Adjusting pupil diameter in accordance with environmental regularities optimizes information transmission at ecologically relevant temporal frequencies.

Pupil diameter is constrained by the pupillary reflex, which naturally adjusts the pupil muscles to the frequency of light. However, not all essential environmental information is contained in the amount of incident light alone. Computations are subsequently required in the brain that go past the abilities of a reflex to take all accessible data. The point of this investigation, supported by the German Research Foundation (DFG), was to see if and to what degree pupil dynamics are controlled completely naturally or whether increasingly complex rhythms in the earth additionally impact them.

A high-speed video camera was used to measure pupil movements of two male rhesus monkeys (Macaca mulatta) and several test subjects of both sexes. On the other hand, subjects were shown sequences of images of human faces at a temporal frequency of two hertz.

A dark background was shown between the images. The alternation of background and image causes the pupil to dilate and contract in rhythm with the images. During the experiments, the order of the images was manipulated they were grouped in pairs so that a particular image always followed a specific other image.

Thus, there are two rhythms to which the pupil reacts: a fast one (two hertz), which results from the alternation of image and background, and one at half that pace (one hertz), which results from the arrangement of the images as pairs. The light itself does not give the sequence of the pairs, and therefore requires an additional computation of environmental rhythms in the brain.

Since the luminance of the faces in all pictures, as well as the dark background in the pauses, remained unchanged, but the arrangement of the pictures varied, conclusions could be drawn about the influence of this additional computation on pupil dynamics.

In addition to the structured sequence, randomly arranged images with the same frequency (two hertz) were shown. A comparison of the results between structured and unstructured image sequences at the same image frequency shows that in both species studied, the pupil follows not only the light-related rhythm of the images but also the more complicated rhythm of the pairs. Pupil movement in a slow (one hertz) rhythm keeps the pupil open longer as if a pair should not be interrupted by the closing of the pupil. This allows more light to reach the retina.

Caspar Schwiedrzik, head of the junior research group Perception and Plasticity, said,The additional information contained in the environment thus complements the information already reaching the retina via the incident light. Furthermore, the study was able to show that this contributes to an improvement in perception, even if the test subjects are not aware that there is a rhythm in the environment. Pupil control is therefore not purely reflexive, but is also influenced by our unconscious thoughts.

More:
Our pupils follow rhythms that arise in the environment - Tech Explorist